The Cost of Relapsing-Remitting Multiple Sclerosis Patients Who Develop Neutralizing Antibodies during Interferon Beta Therapy

Autor: L Santoni, Valentina Di Lecce, Maria Trojano, Vita Direnzo, Mariangela D'Onghia, Sergio Iannazzo, Alessia Manni, Elisa Puma, Damiano Paolicelli, Antonio Iaffaldano, Vito Lavolpe, Carla Tortorella
Rok vydání: 2016
Předmět:
Male
Oncology
Financial Management
Economics
Social Sciences
lcsh:Medicine
Biochemistry
030226 pharmacology & pharmacy
Geographical Locations
Indirect costs
0302 clinical medicine
Cost of Illness
Epidemiology
Medicine and Health Sciences
Ethnicities
lcsh:Science
health care economics and organizations
Multidisciplinary
biology
Neurodegenerative Diseases
Italian People
Europe
Treatment Outcome
Italy
Neurology
Research Design
Cohort
Observational Studies
Female
Antibody
Research Article
Biotechnology
Adult
medicine.medical_specialty
Multiple Sclerosis
Immunology
Research and Analysis Methods
Autoimmune Diseases
03 medical and health sciences
Multiple Sclerosis
Relapsing-Remitting
Internal medicine
Indirect Costs
medicine
Humans
Beta (finance)
Interferon beta
business.industry
Multiple sclerosis
lcsh:R
Biology and Life Sciences
Proteins
Interferon-beta
medicine.disease
Antibodies
Neutralizing
Demyelinating Disorders
Economic Analysis
Wheelchairs
People and Places
biology.protein
Population Groupings
Clinical Immunology
Medical Devices and Equipment
lcsh:Q
Observational study
Interferons
Clinical Medicine
business
Finance
030217 neurology & neurosurgery
Zdroj: PLoS ONE, Vol 11, Iss 7, p e0159214 (2016)
PLoS ONE
ISSN: 1932-6203
DOI: 10.1371/journal.pone.0159214
Popis: Background Relapsing Remitting Multiple Sclerosis (RRMS) patients treated with interferon beta (IFN beta) can develop neutralizing antibodies (NAbs) that reduce treatment efficacy. Several clinical studies explored the association of NAb+ status with increased disease activity. Objective The aim of this study was to estimate the cost of RRMS patients who develop NAbs while treated with IFN beta by the Italian National Healthcare Service (NHS) and the Italian Society perspectives. Methods The clinical data derived from a published observational study on 567 RRMS Italian patients treated with IFN beta. The management cost data derived from the published literature. Cost data were inflated to Euro 2014. Results The annual direct cost to treat a patient was estimated in €15,428 in the NAb+ cohort and €14,317 in the NAb- cohort. The annual societal cost was estimated in €33,890 and €30,790 in NAb+ and NAb- patients, respectively. The cost increase related to the NAb+ status was €3,100 in the Italian societal perspective and €1,111 in the Italian NHS perspective. Conclusion The results of this economic evaluation suggest the presence of an association between NAb+ status and increased costs for the management of RRMS in Italy. Further pharmacoeconomic research will be needed to confirm this first result.
Databáze: OpenAIRE
Externí odkaz: